# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
JP Morgan analyst Anupam Rama maintains Olema Pharmaceuticals (NASDAQ:OLMA) with a Overweight and lowers the price target fr...
HC Wainwright & Co. analyst Emily Bodnar reiterates Olema Pharmaceuticals (NASDAQ:OLMA) with a Buy and maintains $30 pri...
Oppenheimer analyst Matthew Biegler reiterates Olema Pharmaceuticals (NASDAQ:OLMA) with a Outperform and maintains $30 price...
Olema Pharmaceuticals (NASDAQ:OLMA) reported quarterly losses of $(0.54) per share which beat the analyst consensus estimate of...
HC Wainwright & Co. analyst Emily Bodnar reiterates Olema Pharmaceuticals (NASDAQ:OLMA) with a Buy and maintains $30 pri...